Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases II

Jing-Hua Wang1

  • 1Institute of Oriental Medicine, Dongguk University, 32 Dongguk-ro, Goyang 10326, Republic of Korea.

Biomedicines
|April 29, 2025
PubMed

Insights

Hepatobiliary diseases like liver fibrosis and cancer present global health challenges. Research aims to understand their complex causes and find better treatments for these serious liver conditions.

Area of Science:

  • Hepatology and Gastroenterology
  • Oncology
  • Immunology

Background:

  • Hepatobiliary diseases, encompassing liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and cholestatic liver disorders, represent a significant global health burden.
  • The complex pathogenesis and limited therapeutic strategies for these conditions necessitate advanced research.
  • Current understanding of the molecular mechanisms underlying liver disease progression remains incomplete.

Discussion:

  • Investigating the intricate molecular pathways driving hepatobiliary diseases is crucial for developing targeted therapies.
  • Understanding the interplay between genetic, environmental, and lifestyle factors is key to deciphering disease etiology.
  • Exploring novel biomarkers for early detection and prognosis of liver conditions is an active area of research.

Key Insights:

  • Early-stage research focuses on identifying key molecular drivers and cellular processes involved in liver damage and regeneration.
  • Advancements in understanding disease mechanisms pave the way for innovative therapeutic interventions.
  • Multidisciplinary approaches are essential for tackling the complexity of hepatobiliary disorders.

Outlook:

  • Future research will likely focus on personalized medicine approaches for liver diseases, tailoring treatments to individual patient profiles.
  • The development of regenerative medicine and advanced drug delivery systems holds promise for improving patient outcomes.
  • Continued investigation into the gut-liver axis and microbiome's role in hepatobiliary diseases is anticipated.

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
363
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
82
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
28
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
20
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
75